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Abstract
Recently, mutations in the mitochondrial translation optimization factor 1 gene
(MTO1) were identified as causative in children with hypertrophic cardiomyopathy,
lactic acidosis and respiratory chain defect. Here, we describe an MTO1-deficient
mouse model generated by gene trap mutagenesis that mirrors the human
phenotype remarkably well. As in patients, the most prominent signs and symptoms
were cardiovascular and included bradycardia and cardiomyopathy. In addition, the
mutant mice showed a marked worsening of arrhythmias during induction and
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reversal of anaesthesia. The detailed morphological and biochemical workup of
murine hearts indicated that the myocardial damage was due to complex I
deficiency and mitochondrial dysfunction. In contrast, neurological examination was
largely normal in Mto1-deficient mice. A translational consequence of this mouse
model may be to caution against anaesthesia-related cardiac arrhythmias which
may be fatal in patients.
Introduction
Mitochondria are composed of more than 1500 proteins [1], almost all being
encoded by nuclear DNA. In addition, mitochondrial DNA (mtDNA), a circular
DNA with numerous copies in the mitochondrial matrix, encodes 22 transfer-
RNAs (tRNAs), 2 ribosomal RNAs (rRNAs), and 13 polypeptides that are essential
for electron transport and oxidative phosphorylation [2]. Mutations in mtDNA or
nuclear-encoded mitochondrial genes lead to a plethora of metabolic, cardio-
vascular and neurodegenerative diseases and are a main culprit in aging [2, 3, 4].
Nuclear mutations may reside in genes coding for respiratory chain subunits or
their assembly factors or proteins necessary for replication, transcription or
translation of mtDNA [5, 6, 7, 8].
Defects in mitochondrial translation are increasingly recognized as a cause of
human diseases. The intricate machinery of mitochondrial protein synthesis may
be disturbed at any step, including mutations in mtDNA-encoded tRNAs and
rRNAs as well as mutations in nuclear-encoded aminoacyl-tRNA synthetases,
ribosomal proteins, elongation factors, termination factors, mRNA stability
factors, and translation activators [9]. Moreover, four distinct defects have been
described so far in tRNA-modifying enzymes. tRNA modification is critical for
folding and codon recognition. Modifications of the first base of the anticodon,
the so-called wobble position for example, enable tRNAs to recognize multiple
codons.
Mutations in the pseudouridine synthase I (PUS1) gene hamper the process of
pseudouridylation, and lead to the rare recessive syndrome of mitochondrial
myopathy, lactate acidosis and sideroblastic anemia (MLASA) (MIM 600462)
[10]. Mutations of methionyl-tRNA formyltransferase (MTFMT) have been
described in four patients presenting with Leigh syndrome and isolated complex I
or combined oxidative phosphorylation (OXPHOS) deficiency [11, 12]. The
mitochondrial translation optimization factor 1 (MTO1; MGI:1915541) as well as
the tRNA 5-methylaminomethyl-2-thiouridylate methyltransferase
(TRMU5mitochondrial translation optimization factor 2, MTO2) are described
to be responsible for the highly conserved 5-carboxymethylaminomethylation
(mnm5s2U34) modification of the wobble uridine base in glutamine, glutamate,
and lysine tRNAs in bacteria, and yeast thus contributing to the optimization of
mtDNA-dependent protein synthesis [9, 13, 14]. Mutations of TRMU in humans
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cause acute liver failure, benign COX deficiency or Mitochondrial Infantile Liver
Disease [15, 16, 17, 18]. Recently, the first human mutations in MTO1 were
identified by exome sequencing in two siblings and a third unrelated individual
with infantile hypertrophic cardiomyopathy, lactic acidosis and a respiratory
chain defect [19] (MIM 614667). Another study reported MTO1 mutations in five
additional patients with either complex IV or combined complex I and IV
deficiency. In addition to hypertrophic cardiomyopathy and lactic acidosis, some
patients also displayed neurological signs: out of the eight patients described, four
had muscle hypotonia, two showed psychomotor delay;, one had a moderate
bilateral optic atrophy and one suffered from encephalopathy and seizures [20].
Four patients have already died, two from sudden bradycardia, one from cardio-
respiratory arrest, and one from unknown reasons [20]. So far, no mouse model
for this human condition was available.
The Mto1 gene is located on chromosome 9 in the mouse genome and on
chromosome 6 in humans. The mouse Mto1 gene contains 12 exons and encodes
a 669 residues protein exhibiting strong similarity (87%) with its human
homolog. Mto1 is ubiquitously expressed in various tissues, but with a markedly
elevated expression in tissues with high metabolic rates [21].
The aim of this study was to establish a mouse model for human MTO1
deficiency, and to comprehensively investigate its phenotype and biochemistry.
Results
Generation of Mto1 knockdown mice by gene trap mutagenesis
Mutant mice were generated by insertion of the gene trap vector U3CEO into
intron 6 of the Mto1 gene by the German Gene Trap Consortium
(Mto1Gt(G019A03)Wrst); Fig. 1A). The Mto1 specific integration was identified by
sequencing of the fusion transcript and confirmed by DNA sequencing (data not
shown). Quantitative RT-PCR analysis of Mto1 mRNA expression levels in heart
from homozygous Mto1 mutant mice (n59, age 10 weeks) with primers covering
a region 5’ to the integration site of the gene trap vector (thus detecting mutated
and non-mutated transcripts) revealed a significant reduction of Mto1 transcripts
(63%) compared to controls (t-test, p,0.001). The analysis of full-length
transcripts revealed 17% residual transcripts compared to wild-type (Fig. 1B).
Hence, the gene trap created a hypomorphic Mto1 allele.
Two commercially available antibodies were not successful in MTO1 protein
detection by Western blots of mouse tissue preparations. One of these antibodies
did, however, work on isolated mouse embryonic fibroblasts showing a clear
reduction of MTO1 in mutants as compared to controls (Fig. 1C).
Mice were bred on a mixed genetic background (B6129 S/J). No abnormalities
were observed in heterozygous offspring and their breeding gave birth to
homozygous mutants in a Mendelian ratio. Fertility, breeding as well as offspring
ratios were unaffected in homozygous and heterozygous mutants. Lifespan was
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not affected under normal conditions and mutants also reached high ages (Figure
S1 in S1 File).
Phenotypic analysis of Mto1 mice revealed cardiological
alterations
Comprehensive phenotypic analysis was performed in the German Mouse Clinic
[22, 23] with a cohort of 60 young adult mice (15 per sex and genotype) in a
primary screening pipeline. Phenotyping started at the age of 8 weeks and lasted
14 weeks; accordingly, mice from this first analysis underwent pathological
examination at the age of 22 weeks. This primary screen included analyses from 14
medical disciplines including neurology, behavior, nociception, vision, cardio-
vascular function, energy metabolism, immunology, dysmorphology, clinical
chemistry, and molecular phenotyping. We will focus here on the results of the
neurological, behavioral, and cardiovascular analysis, since those were the screens
Fig. 1. Generation ofMto1 knockdown mice by gene trap mutagenesis. (A) Integration of gene trap vector
U3CEO in intron 6 of Mto1. Arrows indicate amplificons for RT-PCR. (B) RT-PCR of heart tissue shows
reduced levels of Mto1 transcripts using primers covering sequences 59 or 39 to the integration site,
***p,0.001. (C) Western blot showing a clear reduction of MTO1 protein in Mto12/2 mouse embryonic
fibroblasts as compared to Mto1+/+ controls.
doi:10.1371/journal.pone.0114918.g001
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of major interest for mitochondrial disorders. In addition to the primary analyses,
we performed further tests in additional cohorts and at different ages.
No obvious changes between mutant and wild-type mice were found in basic
observation tested according to a modified SHIRPA protocol. Body weight at the
age of 10 weeks was significantly reduced (male mutants 25.7¡0.5 g versus
control 28.4¡0.6 g; female mutants 22.1¡0.8 g versus control 24.5¡0.9 g;
p,0.001). Grip strength measurement showed a tendency towards more strength
in mutants. The lighter Mto1 mutant females showed a trend to improved
performance on an accelerating rotarod whereas mutant males showed impaired
performance in advancing trials (data not shown). Replication of neurological
analysis in a cohort of aged mice (16–20 months old) showed again no significant
differences in SHIRPA, grip strength and rotarod performance between mutants
and wild-type (data not shown).
When tested for spontaneous behavior in a novel environment in the modified
Hole Board test, Mto1 mice (aged 8 weeks) of both sexes exhibited increased
horizontal locomotor activity as indicated by total distance travelled, mean
velocity and object exploration, as well as reduced anxiety-related behavior as
measured by increased percentage of time spent on the board in the anxiogenic
centre of the test arena and reduced percentage of time spent at the partition, i.e.
in group contact with the cage mates (Figs. 2A–E). Acoustic startle response
measured in another cohort of mice (9 controls and 10 mutants aged 9 weeks)
showed an altered curve: there was a highly significant interaction between
genotype and startle pulse intensity (F(7,11)54.153, p,0.001), and Bonferroni
posthoc tests revealed a significantly lower response of mutants at maximum dB
(p,0.01, Fig. 2F).
Heart rate was consistently reduced in mutants as compared to controls at
different ages and conditions: (i) awake mice at age 4 months (males: mutant
521.3+/230.1 bpm versus control 566.9+/226.2 bpm; females: mutant 518.2+/
219.3 bpm versus controls 590.3+/222.5 bpm, ANOVA genotype effect p,0.05);
(ii) anaesthetized mice at age 4 months (males: mutant 392.8+/229.3 bpm versus
control 486.1+/216.9 bpm; females: mutant 387.6+/231.8 bpm versus controls
483.7+/214.2 bpm, ANOVA genotype effect p,0.001), Table 1); (iii) awake mice
at age 10 months (mutant 409+/257.4 bpm versus control 645+/236.5 bpm;
p,0.01); (iv) anaesthetized mice at age 15 months (males: mutant 357.6+/
214.6 bpm versus control 466.1+/210.7 bpm; females: mutant 339.1+/
213.7 bpm versus controls 472.1+/212.7 bpm, ANOVA genotype effect
p,0.001; Fig. 3A).
In electrocardiography (ECG) of anaesthetized mice, QRS complex duration
was markedly increased (Fig. 3B). Q-T interval was slightly but significantly
increased and QRS amplitude was significantly decreased in mutants (Table 1).
Qualitative analysis of the ECG demonstrated an extremely high incidence of
arrhythmic events in mutant animals (Table 1). While only one out of 20 control
animals had premature atrial beats, 16 of 19 mutant animals had marked
arrhythmias (p,0.001), mainly atrioventricular blocks, but also premature
ventricular beats or a higher degree of sinoatrial node blocks seen as an
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intermittent complete loss of the P wave. These marked arrhythmias occurred
especially during induction and reversal of anaesthesia. ECG in an additional
cohort of older mice (15 months old, Table S1 in S1 File) confirmed these altered
parameters. ECG without anaesthesia was performed in five mice, and no
arrhythmias were encountered here.
Fig. 2. Behavioral analysis of Mto1 mutant mice using a modified holeboard. Mto12/2mice show
increased horizontal locomotor activity (A) as well as increased mean velocity (B) as compared to controls.
Anxiety-related behavior measured via the time on board (C) and group contact (D) was also significantly
changed; object exploration was increased (E) and acoustic startle response decreased (F), *p,0.05;
**p,0.01.
doi:10.1371/journal.pone.0114918.g002
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At echocardiography, we detected slightly dilated hearts in the knockout mice
with significantly increased diastolic and systolic internal LV diameters (p,0.001
each; Fig. 3C). However, LV function was preserved with insignificant differences
in fractional shortening between both groups (+/+ n56; 37.65131+/23.86948; 2/
2 n57; 32.43615+/21.49116; t-test n.s., Fig. 3D). Posterior wall and septum
thickness did not show significant differences between both groups (Fig. 3E, F).
Heart weight at the age of 22 weeks was significantly increased related to body
weight in mutants compared to controls (mutant heart weight/body
weight50.00654+/20.00065; control hw/bw50.00490+/20.00021; n515,
p,0.05, Fig. 4). In 10 months old animals this was seen as a trend (mutant heart
weight/body weight50.00745+/20.00101; control hw/bw50.00585+/20.00031;
n58, n.s., Fig. 4).
The heart weight differences pointing towards cardiomyopathy were not
reflected in the histopathological analysis of the young hearts. A total of 23 Mto1
mutant mice (13 females, 10 males) and 23 control mice (14 females, 9 males)
were analyzed macroscopically. Histological analysis was performed in 22 mice.
Table 1. ECG parameters (Data are presented as mean +/2 standard error of mean).
Males MALES Females FEMALES
Mto1+/+ Mto 2/2 Mto1+/+ Mto2/2 Sex Genotype Interact.
N5 10 10 10 9 p - value p - value p - value
PQ interval [ms] 37.5+/21.2 36.4+/21.3 40.3+/20.9 41.6+/22.9 p,0.05 n.s. n.s.
P-wave duration [ms] 19.2+/20.5 19.9+/20.6 20+/20.3 19.7+/20.5 n.s. n.s. n.s.
QRS-complex duration
[ms]
10.4+/20.2 13.1+/20.8 10.2+/20.2 13+/20.6 n.s. p,0.001 n.s.
QT interval [ms] 43.1+/20.8 51.6+/22.8 43.3+/20.9 48.4+/23.4 n.s. p,0.01 n.s.
QTcorrected [ms] 38.6+/20.6 40.8+/21.0 38.7+/20.4 37.9+/21.6 n.s. n.s. n.s.
RR interval [ms] 125.2+/24.6 160.3+/211 125.4+/23.8 165.2+/215.8 n.s. p,0.001 n.s.
Heart rate [bpm] 486.1+/216.9 392.8+/229.3 483.7+/214.2 387.6+/231.8 n.s. p,0.001 n.s.
JT interval [ms] 3.1+/20.1 3.1+/20.1 3.3+/20.1 4.3+/20.7 n.s. n.s. n.s.
ST interval [ms] 32.7+/20.8 38.5+/22.4 33+/20.9 35.4+/23 n.s. p,0.05 n.s.
Q amplitude [mV] 0.01+/20 0.01+/20 0.02+/20 0.01+/20 n.s. n.s. n.s.
R amplitude [mV] 3.25+/20.18 3.25+/20.35 3.7+/20.25 3.11+/20.19 n.s. n.s. n.s.
S amplitude [mV] 20.66+/20.08 20.39+/20.27 20.93+/20.16 20.33+/20.07 n.s. p,0.05 n.s.
QRS amplitude [mV] 3.9+/20.22 3.66+/20.53 4.63+/20.32 3.46+/20.18 n.s. p,0.05 n.s.
Arrhythmias [# of animals]
- SVES 0 0 1 0
- VES 0 3 0 4
- AV block 0 5 0 6
- SA block 0 3 0 4
- others 0 8 0 8
Regular ECG 10 2 9 1 p,0.001 Fischer
exact
doi:10.1371/journal.pone.0114918.t001
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Necropsy and histological analysis of 30 organs using HE staining showed no
gross abnormalities in the mutants of both sexes analyzed at the end of the
primary screen test battery at the age of 22 weeks although functional changes
were already detected at this age.
However, histopathological examination of hearts from the 10 months old mice
revealed focal signs of myofiber degeneration (e.g. atrophy and vacuolization) and
Fig. 3. Cardiovascular analysis. (A) Heart rate was reduced in Mto12/2 mutants (white bars) as compared
to controls (black bars) at different ages and under different conditions in three cohorts of mice (4, 10 and 15
months old). (B). Electrocardiography in anaesthetized mice showing increased QRS complex duration in
Mto12/2 mutant mice as compared to controls (C2F) Echocardiography in awake mice showing increased
left ventricular internal diameter in systole and diastole in Mto12/2 mutant mice (C) but no significant
differences in fractional shortening (D), left ventricular posterior wall thickness (E) and intraventricular septum
thickness (F), *p,0.05; ***p,0.001.
doi:10.1371/journal.pone.0114918.g003
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fibrosis in the mutant animals (Fig. 5A, B) as compared to wildtype controls
(Fig. 5C, D). Additionally, unspecific age-related focal mineralization of the
epicardium and myocardium were found in all mutant and control mice. Neither
amyloid deposits (Congo red stain) in the heart nor hemosiderin-laden
pulmonary alveolar macrophages (‘‘heart failure cells’’, Prussian blue staining)
were found in mutants or controls. Analyzing hearts in more detail with
Transmission Electron Microscopy revealed focal necrosis in cardiac muscle cells
with intracristal swelling in mitochondria and dilated sarcoplasmic reticulum in
young adult mutant mice (Fig. 5E) as compared to wildtype controls (Fig. 5F).
MTO1 deficiency leads to reduced mtDNA copy number and
OXPHOS impairment
The relative copy number of heart mtDNA was determined in the same batch of
mice used for expression analysis by calculating the mtDNA ND1 (NADH
dehydrogenase 1) gene copies relative to the nuclear encoded house-keeping gene
ACTB using real-time quantitative PCR [24]. The copy number was reduced to
about 60% of that of controls (Fig. 6A, p50.018, n59).
Since altered translation in mitochondria is supposed to have a major effect on
respiratory chain complex (RCC) proteins, the relative amount of RCC complexes
was tested in a Western blot of heart mitochondria isolated from control and
mutant mice and probed with an antibody cocktail against several subunits of
RCC (Mitosciences). Notably lower amounts of complex I protein were detected
in samples from mutant mice whereas there was no difference between mutants
and control mice in the other complexes (Fig. 6B).
Analyzing the enzymatic activity of RCC complexes revealed a tendency
towards reduced complex I activity in preparations of frozen hearts but this
reduction did not reach significance (n55 each; Fig. 6C). No differences were
Fig. 4. Heart weight related to body weight was significantly increased in Mto12/2 mutant mice as
compared to controls, both in 5 months old mice (n515, *p,0.05) and as a trend in 10 months old mice
(n58, n.s.).
doi:10.1371/journal.pone.0114918.g004
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detected in complex II/III and complex IV activity in heart and liver (data not
shown). Oxygen consumption of freshly isolated heart mitochondria was
measured with Seahorse technology. Maximal respiration rate (MRR) (or state 3u)
of isolated heart mitochondria was calculated as the difference between FCCP-
uncoupled maximal respiration rate and the respiration rate after electron flow
from complex II was inhibited by the complex III inhibitors antimycin A and
myxothiazol. Maximal respiration rate normalized to total protein was
significantly reduced in mutant mitochondria (p50.008, Fig. 6D). The respiratory
Fig. 5. Morphological analysis of heart. (A, C) Focal myocard degeneration in the left ventricle with myofiber
atrophy(arrows) and fibrosis(asterisk) in a 303 day old Mto12/2 mouse (A) as compared to control (C)
(Masson stain, scale bar 200 mm). (B, D) Focal vacuolar degeneration (arrowheads) of myofibers in the heart
of a 303 day old MTO12/2 mouse (B) as compared to control (D) (H&E stain, scale bar 200 mm). (E, F)
Transmission electron microscopy showing degeneration of heart muscle in Mto12/2mice (upper panel E) as
compared to wild-type (lower panel F) at different magnifications (as indicated).
doi:10.1371/journal.pone.0114918.g005
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control ratio (RCR) defined as ratio state3/state4o with succinate as substrate in
the presence of the complex I inhibitor rotenone was not significantly different
(mutants 4.0+/21.5; controls 3.5+/20.9; p50.515). Citrate synthase activity as a
marker for the amount of mitochondrial mass was not altered (data not shown).
A detailed analysis of OXPHOS complexes was carried out using blue native
electrophoresis (BNE). Mitochondrial membranes from hearts were solubilized
and OXPHOS complexes were isolated by BNE. Densitometric quantification of
Coomassie stained protein complexes and in-gel complex I activity confirmed
reduced abundance of complex I in preparations of mutant hearts compared to
controls (Fig. 7). We did not detect any changes in the abundance of any complex
in skeletal muscle, liver and brain. There was a tendency towards reduced complex
I activity also in skeletal muscle but this was not statistically significant
(Supporting Information, Figures S2–5 in S1 File).
Knockdown of Mto1 alters de novo mitochondrial protein
synthesis
To investigate the effects of Mto1 knockdown on mitochondrial translation, we
prepared mouse embryonic fibroblasts (MEFs) from Mto1 mutant and control
mice and performed in vivo metabolic labeling. We observed an altered pattern in
MEFs of Mto1 animals: there was a clear loss of signal intensity for complex I
Fig. 6. Molecular analysis of mouse tissue. (A) mtDNA copy number in hearts of Mto12/2 mutant mice
was significantly reduced as compared to controls (*p,0.05) (B) Respiratory chain complex I was visibly
reduced in a Western Blot using a cocktail of OXPHOS antibodies (Mitosciences.com) in Mto12/2 mutant
mice as compared to controls while respiratory chain complexes II, II, IV and V were unchanged. (C)
Enzymatic activity of complex I in heart tissue lysates was only mildly reduced in Mto12/2 mutant mice but
(D) maximal respiratory capacity was significantly reduced in freshly isolated mitochondria (**p,0.01).
doi:10.1371/journal.pone.0114918.g006
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subunits ND5, ND6 and ND3, while all other mtDNA-encoded proteins showed a
trend to increased levels (Fig. 8).
Mto12/2 mice are more susceptible to paraquat
In a challenge experiment, Mto1 mutant mice and controls were treated with the
herbicide paraquat which has been shown to induce oxidative stress [25]. Nine
animals of each genotype (14 months old) were injected intraperitoneally with
15 mg/kg in 5-day intervals over 9 weeks. Four out of nine mutants died within
this period, while only one out of nine control animals died. Testing the surviving
animals after nine weeks of treatment revealed decreased locomotor activity
measured as the numbers of squares crossed in the first 30 seconds after transfer
to a viewing arena (mutants 2.2¡2.4 squares versus control 18.25¡6.9 squares;
Mann-Whitney Rank Sum Test p,0.001; Figure S6 in S1 File). This was in
contrast to the analysis of the untreated cohorts.
Discussion
While the prevalence and spectrum of human mitochondrial diseases is ever
expanding, defects in mitochondrial translation are relatively rarely described. In
part, this may be due to the severity of these defects and presumed embryonic
lethality in many [25]. Another part of these defects may have escaped diagnosis
so far due to lack of awareness, marked clinical heterogeneity and limited
diagnostic approaches. The recent advent of exome sequencing markedly
facilitates the disclosure of hitherto unassigned disorders, and will likely lead to an
increase in the number of mitochondrial translation diseases. A current example is
Fig. 7. Blue Native Gel electrophoresis of heart tissue. Mitochondrial complexes from wild-type and Mto12/2 heart homogenates were solubilized with
dodecyl-b-d-maltoside and separated by BNE. (A) Coomassie stained 1-D BNE gels, (B) 1-D BNE/complex I in gel activity stain were used for (C)
densitometric quantification of mitochondrial complexes. Complex values from 3 wild-type and 3 Mto12/2 mice are expressed as percent of the wild-type
mean. The Complex I defect is confirmed. Assignment of Coomassie stained complexes: I, complex I or NADH dehydrogenase, V, monomeric complex V or
ATP synthase; III, complex III or cytochrome c reductase; IV, complex IV or cytochrome c oxidase; Ia, in-gel activity stain; *, significant differences (p,0.05);
**, significant differences (p,0.01) by Students t test; error bars indicate standard deviation (SD).
doi:10.1371/journal.pone.0114918.g007
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Fig. 8. Mouse embryonic fibroblasts experiments. In vivo pulse labeling of mitochondrial translation
products in WT and Mto12/2 showing a clear loss of signal intensity for complex I subunits ND5, ND6 and
ND3, while all other mtDNA-encoded proteins showed a trend to increased levels.
doi:10.1371/journal.pone.0114918.g008
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the identification of MTO1 mutations in infantile hypertrophic cardiomyopathy
and lactic acidosis [19, 20]. From the three human patients described in the first
study, two siblings showed metabolic acidosis, high blood lactate and
hypertrophic cardiomyopathy, and died very early (at day 19 and 40, respectively)
from sudden bradycardia. Unrelated patient 3 had a much milder course. He
developed muscle weakness, failure to thrive, and marked hypertrophic
cardiomyopathy in his first months. He had severe metabolic acidosis with high
blood lactate. Dichloroacetate treatment resulted in marked improvement of both
metabolic acidosis and cardiomyopathy, while plasma lactate remained moder-
ately high. Neurological examination showed mild coordination problems and
moderate bilateral optic atrophy [19]. In five additional MTO1 patients, early-
onset hypertrophic cardiomyopathy and lactic acidosis associated with respiratory
chain deficiency was observed as well [20]. One of the patients was diagnosed with
an additional Wolff-Parkinson-White syndrome (MIM: 194200).
The Mto1 knock-down mouse model presented here mirrors the human
phenotype remarkably well. As in patients, the most prominent signs and
symptoms were cardiovascular. Both mice and men show a combination of
cardiomyopathy and cardiac conduction defects. While the cardiomyopathy is
clearly hypertrophic in patients, the findings in mice are more equivocal.
Increased left ventricular inner diameters hint, on the one hand, towards dilated
cardiomyopathy although fractional shortening was not significantly reduced. On
the other hand, increased heart weight despite similar wall thickness suggests
hypertrophic cardiomyopathy as seen in most of the patients described. We
speculate that the mutation and the subsequent impairment of mitochondrial
function leads to heart muscle pathology presenting as dilated or hypertrophic
cardiomyopathy depending on additional environmental factors.
Heart from MTO1 patients has not been investigated so far, but light and
electron microscopy of mutant mouse heart tissue revealed myocardial damage
with signs of multifocal vacuolization and degeneration as well as ultrastructural
changes of mitochondrial morphology.
Bradycardia and cardiac arrhythmias were encountered in both mice and men.
Although the exact mechanism remains unclear, we suggest that the reduced heart
rate in the Mto1-deficient mice mirrors an underlying pathology of the
conduction system. Four out of eight human patients described died in the first
year of life. The cause of death was known in three of them, being described as
cardio-respiratory arrest in one and as sudden bradycardia in two cases. The
mutant mice showed decreased heart rate and marked cardiac arrhythmia, in
particular during induction and reversal of anaesthesia. In contrast to the human
patients, however, we did not encounter fatal consequences of the cardiac
pathology. Recovery from anaesthesia was normal as was the survival in general.
Regarding neurological involvement, psychomotor delay, hypotonia, encepha-
lopathy and seizures have been observed in some Mto1 patients. In the mouse
model, testing of muscle strength and coordination testing did not show major
disturbances. In the modified Hole Board test, Mto1 mice showed increased
horizontal locomotor activity and reduced anxiety-related behaviour, but the
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significance of this finding remains unclear and it has no obvious correlate in
patients. The same is true for the alterations in acoustic startle response that we
found in our Mto1 mutant mice.
Hence, the overall pathology seems milder in Mto1-deficient mice as compared
to patients. This may, at least in part, be due to the residual expression of full-
length Mto1 transcripts in our knockdown mice which most likely ameliorates the
phenotype. In contrast, the human mutations described so far comprise stop
mutations or missense mutations of highly conserved positions, e. g. Ala428Thr
and Thr411Ile mutations.
On the protein level, there was a clear reduction in full-length mutant MTO1
protein in patient fibroblast mitochondria, whereas an additional truncated
MTO1 band was detected [19]. In mice, MTO1 protein levels in fibroblasts were
reduced to a lesser extent suggesting that incomplete splicing of the gene trap
created a hypomorph allele with residual and fully functional protein levels.
Reduced mtDNA content was observed in hearts from mutant mice, a marker
generally associated with less mitochondrial number/mass in those tissues. Patient
data for mtDNA copy number are not available. An up-regulation of
mitochondria and thus mtDNA may be observed in response to oxidative stress
[26]. However, mtDNA proliferation and stability is also affected by insufficient
mitochondrial translation and transcription. Mutations of genes involved in
mtDNA preservation and mitochondrial protein synthesis have been described
now on several levels and are modelled in mutant mice. For example, systemic
inactivation of the nuclear-encoded mitochondrial transcription factor Tfam in
mice proved to be embryonic lethal, while heterozygous Tfam+/2 animals had a
partial reduction in the complex I protein level in heart, but not in liver [27].
Reduction of Tfam also leads to decline of mtDNA copy number [27, 28]. Yeast
strains with defective MTO1 likewise show reduced levels of mtDNA copy
number [14] concordant with our finding in Mto1 mutant mice and also
confirming the highly conserved function of MTO1 during evolution. In the
hearts analyzed there was a marked reduction especially in Complex I abundance
as demonstrated by Western Blot and BNE. In contrast, in skeletal muscle, liver
and brain this reduction was much less, in line with the absence of clinical signs of
respective dysfunctions. This is also in line with the human data [29].
Complex I consists of 45 polypeptides out of which seven are encoded and
transcribed from mtDNA. Complex I deficiency has been shown to cause
cardiomyopathies in mice [30, 31]. Chouchani et al. [31] describe mice with
selective loss of NDUFS4 in heart showing complex I deficiency as well as severe
hypertrophic cardiomyopathy. Quantification of complex I protein in BNE and
visualization of complexes with an antibody cocktail revealed clearly reduced
amounts of complex I protein in Mto1 mutant mice. The reduction of enzymatic
complex I activity, however, was visible but not statistically significant in mouse
heart tissue whereas the other complexes measured were not affected. RCC
activity data measured in fibroblasts from human patients showed reduced
activity especially in complex I and complex IV as well as reduced maximum
respiration rates [29]. Mitochondria of Mto1 mutant mice do also show a clear
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reduction of maximum respiration rates, underscoring the close correlation of
human and mouse data. Hill et al. [32] showed that reducing the bioenergetic
reserve capacity by 4-hydroxynonenal in cardiomyocytes leads to protein
modification and finally cell death. We suggest that the reduced maximal
respiration rate detected in human patients and Mto1 mutant mice indicates
reduced buffering capacity to face metabolic challenges. We could show an effect
of MTO1 deficiency on mitochondrial translation as evident from a metabolic
pulse labeling of de novo synthesized mtDNA-encoded proteins. Interestingly,
loss of MTO1 seemed to selectively affect complex I subunits such as ND5, ND6
and ND3. This finding is consistent with the observed complex I defect in Mto1
knockdown animals. In fibroblasts of human patients, no clear differences had
been detected [29]. While the molecular basis of MTO1 in the regulation of
mammalian mitochondrial translation still remains elusive, our data clearly
highlight MTO1 as an important regulator of translation of complex I subunits.
Recent research indicates that mitochondrial dysfunction can result in
increased propensity to cardiac arrhythmias (reviewed in [33]) via increased ROS
production (e.g. [34], [35]) and impairment of intracellular ion homeostasis and
membrane excitability. In this study, we confirm the link between complex I
deficiency and liability to cardiac arrhythmias. While a detailed analysis of the
molecular mechanisms was beyond the scope of the present study, we found that
Mto1 mutants were more susceptible against paraquat-induced oxidative stress
(increased mortality, hypoactivity). This suggests that oxidative stress is at least
partly involved in the pathogenesis in Mto1 deficiency.
In conclusion, we describe the first mouse model with a defect in mitochondrial
translation. Importantly, this Mto1 knockdown mouse model shows a markedly
similar phenotype as compared to the recently described human Mto1 patients.
The milder phenotype in the mice (less pronounced cardiomyopathy, normal
survival) may be due to residual expression of full-length Mto1 transcripts in our
knockdown mice. Accordingly, there may be much milder affected Mto1 patients
than the ones described so far, and it seems worthwhile to include Mto1
mutations in the differential diagnosis of hereditary cardiomyopathies and
arrhythmias. Of particular importance is, in our opinion, the fact that cardiac
arrhythmias in the mice were only mild to moderate under standard conditions,
but became very severe during induction and reversal of anaesthesia. This points
towards an increased susceptibility of Mto1-deficient mice to additional
environmental triggering, e.g. by anaesthetic drugs. While no anaesthesia-related
complications were described so far in the few known human Mto1 patients, one
translational consequence of this mouse model may be to take precautionary
measures in Mto1 patients when they undergo anaesthesia.
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Materials and Methods
Ethics Statement
Mouse husbandry and all mouse experiments were carried out in accordance with
German legal guidelines and were approved by the responsible animal welfare
authority, Regierung von Oberbayern, Germany.
Mice and genotyping
The embryonic stem cell (ES cell) clone G019A03 (Mto1Gt(G019A03)Wrst) derived
from 129P2/OlaHsd mouse strain was generated using the gene trap vector U3Ceo
[39]. The vector insertion site was determined by 50 rapid amplifications of cDNA
ends (RACE) and sequencing. ES cells were injected into C57BL/6J host
blastocysts to generate chimeras with subsequent germline transmission which
were then mated again with C57BL/6J mice. After germline transmission, the
heterozygous offspring was interbred to generate homozygous mutants (2/2)
and wild-type (+/+) littermate controls. The resulting mixed genetic background
is called B6129 S/J). Heterozygous mice were not analyzed. Genotyping was
performed on Tail DNA using following primers: 8199F 59- AGG TAA CAC GGG
AAG CTA TC -39, 8199R 59- ACC ATA TGA ATC TGA ATC AAC TC -39
(wildtype) and 8102R 59- GAT GTC CTG ACC CAA GGC A -39 (mutant). All
mice were maintained on an ad libitum diet with a 12-h dark–light cycle.
Real-time quantitative PCR
Total RNA of 9 control and 9 Mto12/2 nitrogen frozen mouse hearts was
extracted using TRIZOL Reagent (Invitrogen) and purified with QIAGEN RNeasy
MIDI Kit. For cDNA synthesis with Invitrogen SuperScript First-Strand Synthesis
System, 2 mg RNA was implemented. Real-time quantitative PCR was performed
with the TaqMan Probe-Based Gene Expression Analysis from Applied
Biosystems. Probes: TaqManGene Expression Assay for Mouse Mto1-spanning
exon boundaries but are 59 to the gene trap integration site (Mm00452767_m1) as
well as probes 39 to the integration site (Mm01171633_g1) and TaqManGene
Expression Assay for Mouse Actinb and GAPDH. Data were analysed by StepOne
Software v2.0.
Copy number
DNA was isolated from heart and brain tissue using QIAGEN QIAampDNA Mini
and Blood Mini Kit (cat. no.: 51104; Qiagen, Germany) and following the
manufacturers’ protocol. The samples were diluted to 1 ng/ml. Copy number
variations of mtDNA molecules were defined by quantifying the mtDNA ND1
(NADH dehydrogenase 1) gene relative to the nuclear encoded housekeeping gene
Actb using real-time quantitative PCR [24]. Data was evaluated using the 2‘–
DDCT method.
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Isolation of Mouse Heart Mitochondria
Mice were sacrificed by cervical dislocation; hearts were dissected and
homogenized in M2 buffer (600 mM Sucrose, 5 mM EDTA, 1 mM PMSF,
50 mM Tris/HCl (pH 7.5)). Unbroken cells and cell nuclei were spun down at
650 g for 7 min at 4 C̊ for three times. Protein concentration of the supernatant
was determined using Bradford assay.
Isolation of Mouse Embryonic Fibroblasts (MEFs)
MEFs were isolated from E13.5 embryos of both genotypes and cultured in
DMEM, 10% FKS, 1% sodium pyruvate, 2% Pen/Strep.
Western Blot
Western Blot using an antibody cocktail binding to subunits of the respiratory
chain complexes (MitoProfile Total OXPHOS Rodent WB Antibody Cocktail
(ab110413) was performed following the manufacturer’s instructions. For Mto1
specific labelling ab105066 (abcam) was used.
Determination of specific enzyme activities in isolated
mitochondria
Mitochondria were freeze-thawed to make sure that substrates have full
accessibility to the mitochondrial inner membrane. The measurement of the
specific activity of the individual complexes of the respiratory chain and citrate
synthase as mitochondrial activity marker was performed spectrophotometrically,
as described [34]. All assays were performed at 37 C̊.
Isolation of functional mouse heart mitochondria
Mitochondria were isolated ice cold mitochondrial isolation buffer (MIB)
consisting of 300 mM sucrose, 10 mM HEPES, 0.2 mM EDTA, pH 7.2 at 4 C̊ or
in addition with 1 mg/ml BSA and pH 7.4 at 4 C̊ (MIB+BSA). Mice were killed by
cervical dislocation and the hearts removed and placed in buffer on ice. Fat,
vessels, and blood were removed and the hearts quickly minced in a dry dish on
ice with scissors to a homogenous rate. With 10 ml of MIB+BSA-buffer the heart
sample was homogenized in a Potter-Elvejhem dounce homogenizer with
600 rpm with 10 strokes. Uniform suspension was spun down at 8006g for
10 min at 4 C̊. Supernatant was then centrifuged at 80006g for 15 min at 4 C̊.
Pellet was washed with MIB+BSA and MIB subsequently and resuspended in MIB.
Protein concentration was measured with the Bradford protocol.
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XF24 assay
Mitochondrial assay solution (MAS) components were: 70 mM sucrose, 220 mM
mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 2 mM EGTA, 0.2%
(w/v) fatty acid-free BSA, pH 7.2 at 37 C̊.
Mitochondria were diluted to a concentration of 0,02 mg/ml in MAS buffer
containing 10 mM succinate and 2 mM rotenone and seeded in the seahorse plate
(50 ml of mitochondria to reach 1 mg/well) on ice. Plate was spun down at
20006g for 20 minutes at 4 C̊. After adding pre-warmed 450 ml of MAS buffer
containing 10 mM succinate and 1 mM rotenone plate was incubated for
8 minutes at 37 C̊. Subsequently the following was added to the final
concentration of: 4 mM ADP; 2.5 mg/ml oligomycin, 4 mM FCCP and of 20 of
2 mM antimycin A and 1 mM myxothiazol. Data were analyzed with XF software
using oxygen consumption rate (OCR pmol/min/well).
Electrophoresis and quantification of mitochondrial membrane
complexes
1-D BNE (blue native electrophoresis) was performed as described [36]. Briefly,
10–500 mg wet weight of specimens from heart were homogenized in sucrose
buffer (250 mM sucrose, 20 mM imidazole/HCl, pH 7.0) using a motor-driven
tightly fitting 0.5–1 ml glass/Teflon Potter-Elvehjem homogenizer (1,200 rpm, 30
strokes) and centrifuged for 10 min at 22,0006g to obtain enriched mitochon-
drial membranes. Pellets from 5 mg heart were solubilized in 40 ml solubilization
buffer (50 mM NaCl, 50 mM imidazole/HCl, 2 mM 6-aminohexanoic acid,
1 mM EDTA, pH 7.0) and 2 ml 20% dodecyl-b-d-maltoside. Following 5 min
incubation on ice and 20 min centrifugation at 22,000 g, protein content of
supernatants was measured, equal amounts of protein per sample were
supplemented with 1 ml of a 5% Coomassie blue G-250 suspension in 500 mM 6-
aminohexanoic acid and loaded onto a 3 to 13% acrylamide gradient gel with a
3% sample gel on top. Following BNE, 1-D gels were stained with Coomassie or
by an in gel complex I activity assay (NADH:NBT reductase activity) as described
in [37] with some modifications [38]. The Bio-Rad ChemiDoc XRS system was
used for densitometric quantification.
Modified Hole Board and Prepulse Inhibition (PPI) of the Acoustic
Startle Reflex (ASR)
The modified Hole Board test was performed as previously described by us [39].
The ASR/PPI protocol was adapted to the specifications of our startle equipment
(Med Associates Inc., VT, USA). Background noise (NS5no stimulus) was 65 dB
and trial types for ASR included 7 different stimulus intensities (NS, 70, 80, 90,
100, 110, 120 dB). Trial types for PPI included 4 different prepulse intensities (67,
69, 73, 81 dB), each prepulse preceding the startle pulse (110 dB) by 50 msec
inter-stimulus interval. ASR/PPI were assessed according to the standardized
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phenotyping screens developed by the Eumorphia partners [40] available as
EMPReSSslim protocols (see www.eumodic.org).
Neurological examination
Neurological analysis was performed as described [41]. The mice were analyzed
for basic neurological functions using a modified SHIRPA protocol, measuring
grip strength and rotarod performance for evaluation of motor coordination at
different ages.
Tail-cuff blood pressure measurement
Blood pressure was measured in un-anesthetized mice with a non-invasive tail-
cuff method using the MC4000 Blood Pressure Analysis Systems (Hatteras
Instruments Inc., Cary, North Carolina, USA). Four animals were restrained on a
pre-warmed metal platform in metal boxes. The tails were looped through a tail-
cuff and fixed in a notch containing an optical path with a LED light and a
photosensor. The blood pulse wave in the tail artery is detected as transformed
into an optical pulse signal by measurement of light extinction. Pulse detection,
cuff inflation and pressure evaluation are automated by the system software. After
five initial inflation runs for habituation, 12 measurement runs are performed for
each animal in one session. Runs with movement artifacts are excluded. After one
day of training, in which the animals are habituated to the apparatus and
protocol, the measurements are performed on four consecutive days between 8:30
and 11:30 AM.
Surface limb ECG
ECG was performed in anesthetized (isoflurane/pressured air inhalation) mice by
use of three metal bracelets that are put on the joints of the feet together with
electrode gel. The electrodes were positioned on the front-paws and the left hind
paw, resulting in the bipolar standard limb leads I, II and III and the augmented
unipolar leads AVF, AVR, AVL. ECG is recorded for about seven minutes. Shape
analysis of the ECG traces is performed with the software ECG-auto (EMKA
technologies, Paris, France). For each animal, intervals and amplitudes are
evaluated from five different sets of averaged beats (usually lead II). The
parameter Q-T interval is also corrected for the RR interval. In addition, the
recordings are screened for arrhythmias, including supraventricular and
ventricular extrasystoles and conduction blockages.
Echocardiography
Left ventricular function was evaluated with transthoracic echocardiography using
a Vevo 2100 Imaging System (Visual Sonics) with a 30 MHz probe on conscious
animals. Left ventricular parasternal short and long-axis views were obtained in B-
mode imaging and left ventricular parasternal short-axis views were obtained in
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M-mode imaging at the papillary muscle level. The short axis M-mode images
were used to measure left ventricular end-diastolic internal diameter (LVEDD),
left ventricular end-systolic internal diameter (LVESD), diastolic and systolic
septal wall thickness (SWT) and diastolic and systolic posterior wall thickness
(PWT) in three consecutive beats. Fractional shortening (FS) was calculated as
FS%5[(LVEDD–LVESD)/LVEDD]6100. In addition, heart rate and respiratory
rate were calculated by measuring three systolic intervals, respectively three
respiratory intervals.
Pathology examination
Mice received in the laboratory of pathology were sacrificed with CO2. The
animals were analyzed macroscopically. The body, heart, liver and spleen weight
was determined as well as tibia length. All organs were fixed in 4% neutral
buffered formalin and embedded in paraffin for histological examination. Four-
mm-thick sections of all organs were cut and routinely stained with haematoxylin
and eosin (H&E), Congo red, Masson, Periodic acid-Schiff (PAS) and Prussian
blue. Two pathologists analyzed each slide independently.
Transmission Electron Microscopy
Tissue samples were fixed in 2.5% electron microscopy grade glutaraldehyde in
0.1 M sodium cacodylate buffer pH 7.4 (Science Services, Munich, Germany),
postfixed in 2% aqueous osmium tetraoxide (Dalton, 1955), dehydrated in
gradual ethanol (30–100%) and propylene oxide, embedded in Epon (Merck,
Darmstadt, Germany) and cured for 24 hours at 60 C̊. Semi-thin sections were cut
and stained with toluidine blue. Ultrathin sections of 50 nm were collected onto
200 mesh copper grids, stained with uranyl acetate and lead citrate before
examination by transmission electron microscopy (Zeiss Libra 120 Plus, Carl Zeiss
NTS GmbH, Oberkochen, Germany). Pictures were acquired using a Slow Scan
CCD-camera and iTEM software (Olympus Soft Imaging Solutions, Muenster,
Germany).
Statistical analysis
Data are presented as mean +/2 SEM if not stated otherwise. Statistical analysis
for two groups was performed using Students t-test if not stated otherwise.
Multiple comparisons including sex and genotype were performed using a two
way-ANOVA. Differences were considered to be significant at p,0.05.
Supporting Information
S1 File. Figure S1. Survival plot. No differences were detected under standard
conditions in the survival of mutant mice (n5259) as compared to wild-type
littermates (n5359). Figure S2. CI stain, Quantification of complex I in blue-
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native gels. A, Protein complexes were solubilized with dodecyl-b-d-maltoside,
isolated by blue native electrophoresis and stained by in-gel complex I activity
assay. Upper panel: muscle, central panel: liver, lower panel brain. B, Complex I
was quantified by densitometry (n53). +/+, wild-type mice; 2/2, Mto1 deletion
mutants; BHM, bovine heart mitochondria as ladder; error bars indicate standard
deviation (SD). Figure S3. Muscle: Quantification of OXPHOS complexes in
muscle tissue. A, Mitochondrial complexes were solubilized with dodecyl-b-d-
maltoside and stained with Coomassie. B, Complexes were quantified by
densitometry (n53). Assignment of complexes: I, complex I; III, complex III; IV,
complex IV; V, complex V. +/+, wild-type mice; 2/2, Mto1 deletion mutants;
BHM, bovine heart mitochondria as ladder; error bars indicate standard deviation
(SD). Figure S4. Liver: Quantification of OXPHOS complexes in liver. A,
Mitochondrial complexes were solubilized with dodecyl-b-d-maltoside and
stained with Coomassie. B, Complexes were quantified by densitometry (n53).
Assignment of complexes: I, complex I; III, complex III; IV, complex IV; V,
complex V. +/+, wild-type mice; 2/2, Mto1 deletion mutants; BHM, bovine heart
mitochondria as ladder; error bars indicate standard deviation (SD). Figure S5.
Brain: Quantification of OXPHOS complexes in tissue from brain. A,
Mitochondrial complexes were solubilized with dodecyl-b-d-maltoside and
stained with Coomassie. B, Complexes were quantified by densitometry (n53).
Assignment of complexes: I, complex I; III, complex III; IV, complex IV; V,
complex V. +/+, wild-type mice; 2/2, Mto1 deletion mutants; BHM, bovine heart
mitochondria as ladder; error bars indicate standard deviation (SD). Figure S6.
Brain: locomotor activity after paraquat treatment. Reduced locomotor activity of
mutants (n56) compared to controls (n58) after 9 weeks of paraquat treatment
(p,0.001) measured as the number of floor squares crossed after transfer into a
viewing arena. Table S1. ECG results of an additional cohort of 15 months old
mice confirmed the results found in younger animals (cf. Table 1).
doi:10.1371/journal.pone.0114918.s001 (PDF)
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